APP
Amyloid-beta precursor protein
As of the edition of 20 October 2026, APP (amyloid-beta precursor protein, UniProt P05067) has 15 drugs tested at it and 12 companies on the list, 8 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05067
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 265
- Disease areas
- Mental health; Nervous system; Eye; Nutrition and metabolism; Blood and lymph; Cancer; Heart and blood vessels; Immune system
- Registered trials of its drugs
- 142
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 4 |
| Stopped | 8 |
| Total | 15 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lecanemab | Marketed | Phase 4 | Ends 2035 |
| Donanemab | Marketed | Phase 4 | Ends 2036 |
| Gantenerumab | Stopped | Phase 3 | none listed |
| Bapineuzumab | Stopped | Phase 3 | none listed |
| Aducanumab | Marketed | Phase 3 | Ends 2033 |
| Solanezumab | Stopped | Phase 3 | none listed |
| Crenezumab | Stopped | Phase 3 | none listed |
| Ponezumab | Went quiet | Phase 2 | none listed |
| Vanutide cridificar | Went quiet | Phase 2 | none listed |
| Amilomotide | Went quiet | Phase 2 | none listed |
| Flutafuranol | Stopped | Phase 3 | none listed |
| Valiltramiprosate | Stopped | Phase 3 | none listed |
12 of 15 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 3 |
| Engaged | 1 |
| Total on the list | 12 |
The other 9 companies at APP
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at APP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.